Description: Theriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company was formerly known as Synthetic Biologics, Inc. and changed its name to Theriva Biologics Inc. in October 2022. Theriva Biologics Inc. is headquartered in Rockville, Maryland.
Home Page: therivabio.com
TOVX Technical Analysis
9605 Medical Center Drive
Rockville,
MD
20850
United States
Phone:
301 417 4364
Officers
Name | Title |
---|---|
Mr. Steven A. Shallcross CPA | CEO, CFO, Treasurer, Corp. Sec. & Director |
Dr. Frank Tufaro Ph.D. | Chief Operating Officer |
Vincent I. Perrone | Director of Corp. Communication |
Dr. Vince Wacher Ph.D. | Head of Product and Corp. Devel. |
Dr. Michael Kaleko M.D., Ph.D. | Sr. VP of R&D |
Ms. Lara M. Guzman | Sr. Director of Project Operations |
Exchange: NYSE MKT
Country: US
Currency: US Dollar ($)
Forward PE: | 0 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 0.163 |
Price-to-Sales TTM: | 0 |
IPO Date: | 2006-12-18 |
Fiscal Year End: | December |
Full Time Employees: | 16 |